Table 1.
Baseline patient characteristics.
| All (N = 30) | Ostial-PFA (N = 15) | WACA-PFA (N = 15) | p-value | |
|---|---|---|---|---|
| Demographics | ||||
| Age (years) | 69 (55, 72) | 69 (54, 71) | 68 (59, 73) | 0.388 |
| Gender (male, %) | 67 | 67 | 67 | 1 |
| BMI | 26 (23, 29) | 25 (24, 28) | 27 (23, 30) | 0.767 |
| AF type (paroxysmal, %) | 67 | 67 | 67 | 1 |
| AF diagnosis (months) | 11 (3, 26) | 9 (3, 31) | 11 (4, 25) | 0.492 |
| EHRA class IIa and IIb (%) | 76 | 73 | 80 | 0.267 |
| CHA2DS2VASc score | 2 (1, 3) | 2 (1, 3) | 3 (2, 4) | 0.322 |
| Cardioversion (%) | 37 | 27 | 47 | 0.256 |
| AAD treatment (%) | 43 | 47 | 40 | 0.713 |
| Anticoagulation | 0.067 | |||
| None (%) | 13 | 27 | 0 | |
| DOAC (%) | 77 | 60 | 93 | |
| Vitamin K antagonist (%) | 10 | 13 | 7 | |
| Comorbidities | ||||
| aHT (%) | 60 | 53 | 67 | 0.456 |
| DM (%) | 7 | 0 | 13 | 0.143 |
| CM (%) | 20 | 13 | 27 | 0.361 |
| CAD (%) | 7 | 0 | 13 | 0.143 |
| Stroke/TIA/embolism (%) | 13 | 13 | 13 | 1 |
| OSAS (%) | 3 | 0 | 7 | 0.309 |
| CKD (%) | 7 | 0 | 13 | 0.143 |
| Echocardiography | ||||
| LVEF (%) | 55 (50, 60) | 58 (55, 60) | 52 (41, 55) | 0.035 |
| LA (dilated, %) | 33 | 33 | 42 | 0.656 |
| MR (I–II, %) | 40 | 40 | 46 | 0.743 |
| LAA flow (m/s) | 0.6 ± 0.3 | 0.7 ± 0.2 | 0.5 ± 0.3 | 0.053 |
WACA, wide antral circumferential ablation; BMI, body mass index; AF, atrial fibrillation; AAD, antiarrhythmic drug; DOAC, direct oral anticoagulant; aHT, arterial hypertension; DM, diabetes mellitus; CM, cardiomyopathy; CAD, coronary artery disease; TIA, transient ischemic attack; OSAS, obstructive sleep apnea syndrome; CKD, chronic kidney disease; LVEF, left ventricular ejection fraction, LA, left atria; MR, mitral regurgitation; LAA, left atrial appendage.
Continuous data are given in median and interquartile range (Q1, Q3) and categorical data are given in percentage of N.